|
Gliadel
for pituitary adenomas and craniopharyngiomas
Laws ER Jr, Morris AM,
Maartens N
Department
of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville,
Virginia 22908-0212, USA.
el5g@virginia.edu
Objective. We developed a protocol for a clinical trial of postresection
implantation of Gliadel wafers in patients with aggressive, relentlessly
recurring pituitary adenomas and craniopharyngiomas.
Methods.
Ten patients, nine with pituitary adenomas and one with a craniopharyngioma,
underwent implantation of from two to eight Gliadel wafers.
Results.
No obvious adverse reactions occurred.
Death as a result of disease progression occurred in two patients with malignant
adenomas.
One patient died as a result of a stroke after undergoing five surgical
procedures and prior radiotherapy.
The seven living patients have been followed for 5 to 27 months (mean follow-up,
19 mo).
Four patients have been free of recurrent or residual tumor, two have stable
residual disease, and one has experienced tumor progression.
Conclusion.
The results of this study suggest a role for Gliadel implantation in patients
with recurring aggressive pituitary adenomas and craniopharyngiomas.
PMID: 12925239 [PubMed - in process]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12925239&dopt=Abstract |
